0%
Pipeline Update | Evopoint's Novel Macrolide Antibiotic XNW26018 Tablets Approved for Clinical Trials
2026/11/06

October 20, 2026 — Suzhou Evopoint Biosciences Co., Ltd. (688837.SH) announced that it has received the Notice of Drug Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China. The Company’s self-developed XNW26018 Tablets have been approved for clinical trials by the NMPA, with plans to initiate clinical studies for the treatment of infectious diseases such as community-acquired pneumonia (CAP) caused by microorganisms susceptible to the product. XNW26018 Tablets is a Class 1 innovative drug independently developed by the Company with proprietary intellectual property rights, belonging to the novel macrolide antibiotic class.

Mr. Le Meijie, Chief Executive Officer of Evopoint, stated: “Community-acquired bacterial pneumonia (CABP) is one of the most common infectious diseases, referring to parenchymal lung inflammation acquired outside the hospital setting. The disease has a particularly high incidence among children and the elderly, with major pathogens including Streptococcus pneumoniae, Mycoplasma pneumoniae, Haemophilus influenzae, among others, representing a significant unmet medical need. Preclinical studies have demonstrated that XNW26018 exhibits a favorable antibacterial spectrum and antibacterial characteristics both in vitro and in vivo, with a broad spectrum of activity that covers the major pathogenic bacteria responsible for community-acquired bacterial pneumonia.”

Risk Disclosure

This press release contains certain forward-looking statements based on the Company’s current expectations and beliefs. Actual results may differ materially from those forward-looking statements due to various factors. In accordance with applicable laws and regulations governing drug registration, after obtaining clinical trial approval, the drug must still undergo clinical trials in compliance with the requirements set out in the clinical trial approval notice, and may only be marketed and sold after passing the review and approval of the drug regulatory authority. The receipt of the Notice of Drug Clinical Trial Approval for XNW26018 Tablets is not expected to have a material impact on the Company’s short-term operating results. Pharmaceutical products are characterized by high technology, high risk, and high added value. The early-stage drug research and development, as well as the entire process from development, clinical trial application to production, involves long cycles and numerous stages, and is susceptible to influences from various factors including technology, regulatory approval, and policy. There are numerous uncertainties regarding the progress and results of clinical trials, as well as the future competitive landscape of the product. The Company will actively advance the aforementioned research and development projects, and will strictly fulfill its information disclosure obligations in accordance with relevant regulations as the projects progress. Investors are advised to exercise caution and be mindful of investment risks.

Previous Next